Quality of life assessment during clinical trials: Application to the multicentre phase II study of fotemustine in advanced non small cell lung carcinoma (NSCLC)

1993 ◽  
Vol 29 ◽  
pp. S161
Author(s):  
J. Berille ◽  
C. Ressayre ◽  
J.L. Pujol ◽  
A. Monnier ◽  
J.Y. Douillard ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii Study ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Life Assessment ◽  
Small Cell Lung ◽  
Quality Of Life Assessment ◽  
Cell Lung Carcinoma ◽  
Multicentre Phase

Post-operative outcomes and quality of life assessment after thoracoscopic lobectomy for Non-small-cell lung cancer in octogenarians: Analysis from a national database

2021 ◽  
Vol 37 ◽  
pp. 101530
Author(s):  
Stefano Bongiolatti ◽  
Alessandro Gonfiotti ◽  
Sara Borgianni ◽  
Roberto Crisci ◽  
Carlo Curcio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Life Assessment ◽  
National Database ◽  
Small Cell Lung ◽  
Quality Of Life Assessment ◽  
Operative Outcomes

Association of pretreatment financial toxicity with time to treatment for patients with head and neck carcinoma and lung carcinoma.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 131-131
Author(s):  
Sharon Lam ◽  
Nicolas Schlecht ◽  
Gregory Rosenblatt ◽  
Vikas Mehta
Keyword(s):  
Quality Of Life ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Treatment Delay ◽  
Small Cell ◽  
Financial Toxicity ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Younger Age

131 Background: Financial toxicity (FT) describes objective and subjective burden of costs associated with medical care. Patients with head and neck cancer (HNC) and lung carcinoma are acutely impacted by FT, as these cancers disproportionately occur in populations that are poor, unemployed, and/or of minority backgrounds compared to patients with other cancers. Our group recently published results showing delay in time to treatment initiation (TTI) was associated with poorer survival in HNC patients. Another study reported that FT was associated with worse progression-free survival in non-small cell lung cancer patients. In this study, we sought to investigate the association between FT, TTI and clinical outcomes among HNC and lung carcinoma patients, as well as predictors of FT. Methods: A retrospective analysis of 140 patients diagnosed with either HNC or lung carcinoma between January 2007 and March 2018 with quality-of-life data collected prospectively at the time of radiation oncology treatment was conducted. Participants responded to a question about their experience on ‘financial difficulties’ with a 4-point Likert Scale within the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) quality of life assessment. FT was low when patients indicated ‘1’ (not at all) or ‘2’ (a little), and high if patients indicated ‘3’ (quite a bit), and ‘4’ (very much). Chi-square test and Student’s t-test were used to compare characteristics of patients with and without FT. The association between FT and TTI and survival outcomes were analyzed using the Kaplan-Meier methods and Cox proportional-hazards regression models. Results: The study sample included 70 patients with HNC (mean [SD] age, 64.3 [12.0]; 62.7% male) and 70 patients with lung carcinoma (mean [SD] age, 69.1 [10.2]; 38.0% male). Over half (N = 80, 55.2%) reported experiencing financial toxicity (64% HNC vs. 45.7% lung carcinoma). Younger age (< 60 years), having Medicaid, and having small-cell lung carcinoma were associated with greater FT (p = 0.049, p = 0.042, p = 0.034, respectively). Patients who reported having poorer health and quality of life also experienced greater FT (p = 0.030, p = 0.016, respectively). HNC patients who experienced greater FT were less likely to experience treatment delay (p = 0.035). After adjusting for age, sex, ethnicity, tumor site, and tumor stage, FT was associated with worse survival outcomes in all patients (HR = 1.52, 95% CI 1.06-2.19). Conclusions: Greater FT was associated with younger age, having Medicaid, and having small-cell lung carcinoma. HNC patients who experienced greater FT were less likely to experience treatment delay, which suggests that delay may not be a causative factor for the worsened survival seen with patients who report FT.

scholarly journals Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer

1992 ◽  
Vol 3 (10) ◽  
pp. 825-831 ◽  
Author(s):  
C. Hürny ◽  
J. Bernhard ◽  
R. Joss ◽  
Y. Willems ◽  
F. Cavalli ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Life Assessment ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Quality Of Life Assessment ◽  
Phase Iii Trial

Quality of life assessment during chemotherapy for non-small cell lung cancer

1990 ◽  
Vol 26 (6) ◽  
pp. 706-708 ◽  
Author(s):  
Paula K. Maasilta ◽  
Jukka K. Rautonen ◽  
Madeleine T. Mattson ◽  
Karin V. Mattson
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Life Assessment ◽  
Small Cell Lung ◽  
Quality Of Life Assessment

Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593

2001 ◽  
Vol 50 (5) ◽  
pp. 1199-1206 ◽  
Author(s):  
Richard M Auchter ◽  
Denise Scholtens ◽  
Sudeshna Adak ◽  
Henry Wagner ◽  
David F Cella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Life Assessment ◽  
Small Cell Lung ◽  
Quality Of Life Assessment ◽  
Accelerated Radiotherapy ◽  
Lung Cancer Patients

scholarly journals Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks

2012 ◽  
Vol 109 (12) ◽  
pp. 2231-2239 ◽  
Author(s):  
Barbara S. van der Meij ◽  
Coline P. Schoonbeek ◽  
Egbert F. Smit ◽  
Maurizio Muscaritoli ◽  
Paul A. M. van Leeuwen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prognostic Value ◽  
Cancer Cachexia ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Stage Iii Nsclc

Despite the development of consensus-based frameworks to define cancer cachexia, the validity and usefulness of these frameworks are relatively unknown. The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III non-small-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. In forty patients at diagnosis of stage III NSCLC, weight loss, fat-free mass, handgrip strength, anorexia and serum biochemistry, assessed before the first chemotherapy, were used to define ‘cancer cachexia’ or ‘cachexia’. The cancer-specific framework also classified for pre-cachexia and refractory cachexia. Additionally, quality of life was assessed by the European Organisation for Research and Treatment of Cancer – Quality of Life Questionnaire C30. Groups were compared using independent t tests, ANOVA, Kaplan–Meier and Cox survival analyses. Based on the cancer-specific framework, pre-cachexia was present in nine patients (23 %) and cancer cachexia was present in seven patients (18 %). Cancer cachexia was associated with a reduced quality of life (P= 0·03) and shorter survival (hazard ratio (HR) = 2·9; P= 0·04). When using the general framework, cachexia was present in eleven patients (28 %), and was associated with a reduced quality of life (P= 0·08) and shorter survival (HR = 4·4; P= 0·001). In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. For both frameworks, cachexia appears to be associated with a reduced quality of life and shorter survival. Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients.

The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy

2000 ◽  
Vol 55 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Hans Langendijk ◽  
Neil K Aaronson ◽  
Jos M.A de Jong ◽  
Guul P.M ten Velde ◽  
Martin J Muller ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Eortc Qlq C30 ◽  
Eortc Qlq
Sign in / Sign up

Export Citation Format

Share Document